Table 1 % Cell growth inhibition of NCI 60 cancer cell lines exhibited by investigated final compounds (4c, 4d, 5, 9a, 9b, 11a, 11b, 13b, 13c, 15b, 15c)

Leukemia

CCRF-CEM

–

–

–

–

–

–

25.35

–

12.13

–

–

HL-60(TB)

–

–

–

–

–

–

–

0.37

–

–

57.96

K-562

–

–

–

–

3.50

0.06

32.81

2.89

24.78

2.05

82.73

MOLT-4

–

–

–

–

–

1.28

–

–

–

–

67.84

RPMI-8226

–

–

–

–

–

–

28.90

13.64

34.97

–

16.44

SR

4.7

1.71

–

–

9.02

18.74

42.22

17.85

6.00

3.55

89.33

Non-small cell lung cancer

A549/ATCC

9.11

–

–

–

–

4.86

–

–

21.56

–

43.44

EKVX

24.27

15.79

18.84

–

38.49

47.43

16.02

–

16.78

1.92

65.42

HOP-62

32.04

13.42

9.49

2.73

27.70

30.47

11.28

–

12.01

1.01

62.67

HOP-92

16.44

11.86

11.03

6.83

4.65

–

15.37

6.38

11.45

5.79

50.24

NCI-H226

11.4

4.95

8.23

–

12.22

19.14

16.81

–

1.09

3.30

70.05

NCI-H23

7.13

3.70

13.28

–

9.28

12.04

17.37

3.53

25.93

72.85

62.20

NCI-H322M

–

–

3.18

–

–

–

–

–

–

–

47.17

NCI-H460

–

–

–

–

1.64

–

4.26

–

7.04

–

83.16

NCI-H522

–

0.13

5.36

5.55

–

–

6.92

1.35

2.31

4.97

–

Colon cancer

COLO205

–

–

–

–

–

–

–

–

1.80

–

74.25

HCC-2998

–

–

–

–

–

–

–

–

–

–

26.06

HCT-116

–

–

–

–

–

–

13.39

–

21.94

7.30

73.04

HCT-15

–

–

–

–

–

–

9.43

–

12.04

2.59

70.99

HT29

–

–

–

–

–

–

–

–

8.13

–

82.12

KM12

49.21

4.63

1.51

–

43.89

13.94

77.28

62.68

59.02

49.11

40.78

SW-620

4.95

–

–

–

–

–

4.60

–

–

–

78.60

CNS cancer

SF-268

16.39

–

2.04

–

3.48

11.32

1.02

–

–

–

22.77

SF-295

–

0.84

–

–

–

–

0.84

–

–

–

29.41

SF-539

2.79

3.69

–

–

5.04

–

–

–

1.96

–

66.38

SNB-19

–

–

0.31

–

–

–

–

–

–

–

69.03

SNB-75

44.3

18.84

16.52

4.88

31.29

32.80

16.61

–

–

1.02

66.62

U251

–

0.06

2.06

–

–

–

14.38

–

–

–

58.05

Melanoma

LOX IMVI

6.93

–

–

–

7.22

3.30

8.30

–

9.06

–

64.90

MALME-3 M

0.23

–

–

–

2.09

3.16

–

–

–

–

53.15

M14

2.15

6.04

2.01

–

1.44

–

0.40

–

–

–

81.48

MDA-MB-435

–

–

–

–

–

2.04

31.96

–

1.15

–

152.70

SK-MEL-2

–

–

2.36

–

–

–

–

–

–

–

37.92

SK-MEL-28

–

–

–

–

–

–

–

–

–

–

38.68

SK-MEL-5

1.74

1.52

1.04

–

6.95

5.94

15.15

1.85

5.29

0.02

73.25

UACC-257

–

–

–

–

–

–

–

–

–

–

28.37

UACC-62

–

3.05

4.35

–

7.84

–

3.27

–

–

–

75.08

Ovarian Cancer

IGROV1

24.07

23.49

18.58

–

21.31

32.70

23.48

–

5.94

–

70.47

OVCAR-3

–

–

–

–

–

–

–

–

3.91

–

84.64

OVCAR-4

13.33

1.55

–

–

7.67

12.63

11.49

–

3.49

–

59.42

OVCAR-5

0.03

–

–

–

–

–

–

–

–

–

39.57

OVCAR-8

–

0.12

–

0.63

–

–

1.39

–

–

–

44.31

NCI/ADR-RES

–

–

–

–

–

–

–

–

–

–

59.19

SK-OV-3

–

0.47

5.43

–

–

–

–

–

3.75

–

44.97

Renal cancer

786-0

4.08

1.80

–

–

4.99

0.56

–

3.85

–

–

47.06

A498

20.07

–

–

–

9.11

–

–

1.46

–

–

107.94

ACHN

1.58

6.28

10.89

1.90

10.46

7.22

16.74

–

–

–

59.26

CAKI-1

29.12

13.50

11.2

8.65

27.60

34.72

48.43

5.62

30.80

5.21

67.07

RXF 393

29.59

–

–

–

–

26.16

–

–

–

–

120.47

SN12C

24.77

–

–

–

20.49

22.86

–

1.75

11.59

1.23

32.00

TK-10

19.11

–

–

–

–

–

–

–

–

–

24.34

UO-31

49.71

27.49

34.58

18.04

43.70

44.00

39.47

7.60

16.22

18.32

51.58

Prostate cancer

PC-3

7.71

10.72

5.36

–

7.10

7.36

14.22

–

15.30

5.91

31.40

DU-145

–

–

–

–

–

2.90

–

–

–

–

59.52

Breast cancer

MCF7

1.59

12.41

6.19

6.01

4.97

23.02

37.23

12.64

28.08

15.02

77.30

MDA-MB-231/ATCC

4.54

7.66

5.14

–

3.83

16.48

8.34

0.12

10.67

–

52.05

HS 578T

0.5

–

–

–

–

–

–

–

–

–

68.54

BT-549

–

1.21

0.96

–

27.15

6.46

–

13.62

–

T-47D

–

14.77

7.19

–

–

6.76

27.51

6.91

–

7.81

58.82

MDA-MB-468

–

–

–

–

–

–

7.66

–

23.54

–

102.28

MEAN % Growth inhibition

3.71

 − 1.47

 − 1.25

 − 6.41

2.55

2.58

7.38

 − 3.98

3.28

 − 2.47

61.83